Compare Heron Therapeutics Inc (HRTX) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs NEOS S&P 500 High Income ETF — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while NEOS S&P 500 High Income ETF trades at $54.15. The key difference: NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | SPYI | |
|---|---|---|
Market Cap | $63.41M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $1.49 | $54.19 |
52-Week Low | $0.32 | $47.98 |
Enterprise Value | $161.31M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
SPYI trades at $54.18, up 0.39% today, with a bullish technical signal driven by moving averages. The ETF focuses on generating high income through an options overlay on the S&P 500, offering monthly dividends. Recent news highlights its role in retirement income strategies, though some articles caution about yield sustainability.
The outlook hinges on volatility-driven income generation, with potential for steady returns if market conditions persist. Risks include declining volatility reducing payouts and principal erosion concerns. Investors should weigh the high yield against the strategy's dependency on options premiums.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
